This article covers multiple oral and poster presentations dedicated to gene therapy as a treatment for haemophilia A and B, which took place at the International Society on Thrombosis and Haemostasis (ISTH) Congress, 9th–13th July 2022. The article highlights updates from clinical trials of adeno-associated virus-based gene therapy products, guidance on the real-world monitoring of patients with haemophilia who have received gene therapy, and accentuates the unmet needs and challenges associated with gene therapy.
EMJ Hematology 10 [Supplement 5] . 2022
September 2022
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Thank you!
Please share some more information on the rating you have given